Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Summary

This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and 68Ga-PSMA are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET/CT scan. It is not yet known whether giving fluciclovine F18 or 68Ga-PSMA may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.

Timeline

Start

2019-05-10

Primary completion

2025-05-31

Completion

2025-12-31

Publications

• Abiodun-Ojo OA, Jani AB, Goyal S, Lawal IO, Halkar RK, Dhere V, Shelton JW, Patel PR, Schreibmann E, Hershatter B, Patel SA, Hanasoge S, Sebastian NT, Schuster DM. 18F-Fluciclovine or 68Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial. Radiology. 2026 Jun;319(3):e251874. doi: 10.1148/radiol.251874.

Drugs

Indications